Chili compound put to the test as a cough silencer
NCT ID NCT04125563
First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether taking capsaicin, the compound that gives chili peppers their heat, can desensitize the cough reflex and reduce symptoms in people with chronic idiopathic cough, a persistent cough with no identifiable cause. About 55 adults with this condition will receive either capsaicin capsules or a placebo for four weeks, then switch after a two-week break. Researchers will measure cough sensitivity and use a cough monitor to see if the treatment reduces coughing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Capsaicin (from chili extract) taken as oral capsules
- What this could lead to
- If it works, this could point toward a new treatment for chronic idiopathic cough, a condition with no clear cause and few effective options.
- What could go wrong
- This is a small, early-stage trial, so results may not hold up in larger studies. Capsaicin can cause stomach irritation or burning sensations, and it may not reduce coughing in everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
55 people
The number who actually took part.
- Started
-
Jun 2019
- Finished
-
Aug 2022
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Out-patients, men and women * Age 18-75 years * Present non-smoker * A diagnosis of CIC, set by a trained specialised physician * Exceeding the cut off limit for the Swedish version of the Hull Airway Reflux Questionnaire (HARQ-S): (a total score of ≥13 points) * At screening visit reporting daily, troublesome coughing and an easily evoked cough reflex since at least two months * At screening visit having a positive capsaicin inhalation cough test Exclusion Criteria: * Known or suspected chili allergy * Known or suspected allergy to the colorant Tartrazine (FD\&C Yellow #6) * Any kind of diabetes * Treatment the preceding month with any kind of chili medication or food supplement containing capsaicin or having a diet including chili in treatment purpose * Treatment the preceding month with medication according to the study protocol * Pregnancy, breast-feeding, planned pregnancy during the study and fertile women not using acceptable contraceptive measures, as judged by the investigator * Suspected poor capability to follow instructions of the study, e.g. because of a history of drug abuse, difficult to read and/or understand Swedish or any other reason, as judged by the investigator * Airway infection the last 4 weeks before study start * Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study * Any clinically relevant abnormal findings in physical examination, vital signs at baseline visit, which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study * Previous randomisation of treatment in the present study * Participation in another clinical study 30 days prior to and during this study * Smoking during the last ten years or/and \>10 pack years * Known alcohol and/or drug abuse * The participants will be asked for any season allergy or other allergy and for allergen exposure. The study start date will be adjusted to season or another possible allergen exposure.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cough are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allergy clinic, Sahlgrenska University Hospital
Gothenburg, Västra Götaland County, 413 45, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could skipping the breathing tube ease recovery after throat surgery?
- Timing the dose: a new strategy to stop coughing under anesthesia?
- Can a simple breathing test unlock the secrets of chronic cough?
- Could a new dissolving tablet quiet coughs? safety trial begins
- New pill aims to silence chronic cough that Won't quit
- Asthma in children may hide behind unusual symptoms, study reveals